Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: XR-B Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

NCT00865657
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 17, 2026, 8:53 PM EDT
Terminated Phase 2 Interventional Results available

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

NCT02531308
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Metformin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, pegfilgrastim
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence and Food Effect of 250mg of Lamotrigine XR

NCT00605371
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine tablet, Lamotrigine caplet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333
View directory record Official record
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

NCT00694759
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, metformin, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

NCT00865072
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

NCT03627936
View directory record Official record
Conditions
Healthy Participants
Interventions
Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 17, 2026, 8:53 PM EDT
Recruiting Phase 4 Interventional

Injectable Buprenorphine in Prison: A Preference Trial

NCT06880718
View directory record Official record
Conditions
Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder, Buprenorphine
Interventions
Brixadi (Injectable Buprenorphine), Sublocade
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

NCT02039258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CANA/MET XR FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 8:53 PM EDT
Withdrawn Phase 4 Interventional

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

NCT05481112
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Buprenorphine Injection
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02071368
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/500, CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 4 Interventional

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

NCT04219540
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B (SUBLOCADETM), XR-NTX
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 4 Interventional

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

NCT00323947
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Epilepsy
Interventions
Extended Release Methylphenidate (OROS-Methylphenidate)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851212
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

NCT01441869
View directory record Official record
Conditions
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions
Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 17, 2026, 8:53 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Combined Injectable Treatment for HIV and OUD

NCT05991622
View directory record Official record
Conditions
Human Immunodeficiency Virus, Opioid Use Disorder
Interventions
Combined LAI Treatment: Cabenuva and Sublocade
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed No phase listed Observational

Drug Interaction With Envarsus XR and Grapefruit Juice

NCT03916380
View directory record Official record
Conditions
Kidney Transplant; Complications, Drug Interaction Food
Interventions
Grapefruit Juice
Dietary Supplement
Lead sponsor
Shirley M. Tsunoda
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 17, 2026, 8:53 PM EDT
Active, not recruiting Phase 4 Interventional

Envarsus XR® in Adolescent Renal Transplant Recipients

NCT03266393
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Grafting, Kidney
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

NCT00865839
View directory record Official record
Conditions
Healthy
Interventions
Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 17, 2026, 8:53 PM EDT